Format

Send to

Choose Destination
J Surg Oncol. 2015 Jul;112(1):103-6. doi: 10.1002/jso.23961. Epub 2015 Jul 14.

Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma.

Author information

1
Moffitt Cancer Center, Tampa, Florida.
2
Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida.
3
Sarcoma Department, Moffitt Cancer Center, Tampa, Florida.

Abstract

BACKGROUND:

Pulmonary metastasectomy (PM) for metastatic sarcoma can result in long-term survival. The purpose of this study was to describe factors associated with survival in a series of patients undergoing PM for metastatic sarcoma.

METHODS:

We reviewed all patients undergoing PM for metastatic sarcoma over a 12-year period (2000-2012). Multivariate analyses were used to identify factors associated with outcomes. Survival was calculated with Kaplan-Meier and Cox proportional hazard models.

RESULTS:

A total of 120 patients underwent PM with a median follow-up was 48 months. Among 81 (85%) patients who presented with local disease, the median disease free interval (DFI) was 13 months and median overall survival (OS) was 48 months. Fourteen patients (15%) had synchronous metastasis with a median OS of 21 months. On multivariate analysis, synchronous metastasis (P = 0.005), older age (P = 0.02), and number of lung lesions (P = 0.003) were associated with poor survival. The median OS of patients with a DFI ≥12 versus <12 months following primary resection was 93 and 43 months (P = 0.004).

CONCLUSION:

While patients with a DFI >12 months have the best OS following PM, patients with a DFI <12 months also have excellent outcomes as compared to systemic therapy and should be considered for PM.

KEYWORDS:

bone; outcomes; pulmonary metastasectomy; sarcoma; soft tissue

PMID:
26179670
DOI:
10.1002/jso.23961
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center